# Determining Factors and The Progression of The Onset of Alzheimer’s Disease and Cognitive Impairment

https://www.neurodegenerationresearch.eu/survey/determining-factors-and-the-progression-of-the-onset-of-alzheimers-disease-and-cognitive-impairment/

**Title of cohort**

Determining Factors and The Progression of The Onset of Alzheimer's Disease and Cognitive Impairment

**Acronym for cohort**

MEMENTO

**Name of Principal Investigator - Title**

Prof

**Name of Principal Investigator - First name**

Chêne/Carole

**Name of Principal Investigator - Last name**

Geneviève/Dufouil

**Address of institution -Institution**

CHU Bordeaux

**Address of institution - Street address**

146 rue Léo Saignat

**Address of institution - City**

Bordeaux

**Address of institution - Postcode**

33076

**Country**

France

**Website**

**Contact email**

[email protected]ped.u-bordeaux2.fr | [email protected]

**Funding source**

Alzheimer's Foundation Plan (Fondation Plan Alzheimer), PHRC, GE Healthcare, AVID

**Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions?**

Alzheimer's disease and other dementias

**Q1b. When are studies on the above condition(s) expected to become possible?**

2016-2020

**Q2a. In a single sentence what is the stated aim of the cohort?**

Identification and validation of biomarkers or combination of biomarkers that best predict the occurrence of dementia

**Q2b. What distinguishes this cohort from other population cohorts?**

The largest naturalistic cohort on brain health, with a rigorous prospective design, extensive follow-up (at least 5 years), standardized procedures, multiple biomarkers (imaging, blood CSF) assessed with standardized acquisitions and analyses

**Q3a. i) Number of publications that involve use of your cohort to date**

0

**Q3a.ii) Please give up to three examples of studies to date (Principal Investigator, Institution, Title of Study)**

B Dubois, APHP, The Insight Cohort| B Dubois, APHP, The Insight Cohort

**Q3b. If data on research outputs are already available please paste the publication list/other data or provide a link to where these data are publicly available**
**Q3c. If no research has been done as yet, please explain in a few sentences what information (i.e. research findings) you expect will be gained from the population**
**Q4a. Study criteria: what is the age range of participants at recruitment? Age in years From:**

19

**Q4a. Study criteria: what is the age range of participants at recruitment? To:**

no limit

**Q4b. Study criteria: what are the inclusion criteria?**

Adults, either a recently evaluated (< 6 months) cognitive performance worse than one standard deviation to the mean in one or more domains or an isolated cognitive complaint (patient aged ? 60 years), Nondemented, Clinical Dementia Rating Scale (CDR) ?0.5

**Q4c. Study criteria: what are the exclusion criteria?**

Guardianship, Meeting brain MRI exclusion criteria or refusing MRI, Illiteracy

**Q5. What is the size of the cohort (i.e. how many participants have enrolled)?**

1,000-5,000 participants

**Q6a. Please describe what measures are used to characterise participants**

Demographics, neuropsychometric test, neuroimaging, blood and CSF biomarkers, DNA

**Q6b. Are there additional measures for participants with a clinical disorder?**

No

**Q6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)?**

Yes

**If yes please specify**

Dementia

**Q7. What is the study design (select all that apply)?**

Prospective cohort|Longitudinal

**Q8. Are your cases matched by**
**Q9a. Does your study include a specialised subset of control participants?**

Yes

**Q9b. If your study includes a specialised subset of control participants please describe**

by definition controls are those who do not get the disease at a give,n time of analysis

**Q10a. i) Please enter the data collection start date**

01/01/2011

**Q10a. ii) Please enter the data collection end date**

01/01/2019

**Q10a. iii) Is data collection for this study**

Data collection ongoing| Data analysis ongoing

**Q10b. If data collection is ongoing, are there plans to continue the cohort study beyond the current projected end date?**

Yes - intend to apply for funding

**Q11. Is data collected**

Only through the study

**Other please specify here**
**Q12. Is there a system in place to enable re-contact with patients to ask about participation in future studies?**

Yes (participants given permission to be re-contacted via PIs)

**Q13a. Please give information on the format and availability of data stored in a database (1)**

Data summarised in database

**% available**

100

**Q13a. Please give information on the format and availability of data stored in a database (2)**

Database is web-based

**% available**

100

**Q13a. Please give information on the format and availability of data stored in a database (3)**

No

**% available**
**Q13a. Please give information on the format and availability of data stored in a database (4)**

No

**% available**
**Other (please specify)**
**% available**

**Q13b. Please give information on the format and availability of data held as individual records (1)**

Data is held as individual records

**% available**
**Q13b. Please give information on the format and availability of data held as individual records (2)**

Data is web-based

**% available**
**Q13b. Please give information on the format and availability of data held as individual records (3)**

Data held on computer based records

**% available**
**Q13b. Please give information on the format and availability of data held as individual records (4)**

No

**% available**
**Please specify language used**

French

**Q14a. Is data available to other groups?**

Yes

**Q14b. If data is available to other groups what is the access policy/mechanisms for access?**

Apply to PI or co-ordinator at resource| Access independent of collaboration with PI| Access committee mechanism| Access committee mechanism| International access| Access to industry| Access for pilot studies permitted| Resource has own ethics approval so usually no need for separate external ethics approval| Data are not distributed, access through our secured system

**Q15. What data sharing policy is specified as a condition of use?**

No requirement to make data publicly available

**Q16a. Are tissues/samples/DNA available to other groups?**

Yes

**Q16b i) If yes, please describe below:**

Living donors: blood| Living donors: blood derivatives| Living donors: DNA| Living donors:

cerebro-spinal fluid| Post-mortem donors: brain

**Q16b. ii) In what form are tissues/samples/DNA supplied?**

Secondary samples: plasma| Secondary samples: DNA| Secondary samples: RNA

**Q16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q14 above)?**

Yes

**Q17. Is information on biological characteristics available to other groups?**

Yes, for all the cohort

**Number of Patients**
**% of total cohort**

**Types:**
Population Cohorts

**Member States:**
France

**Diseases:**
Alzheimer's disease & other dementias

**Years:**
2016

**Database Categories:**
N/A

**Database Tags:**
N/A